DOCSLIB.ORG

Cytotoxic and Apoptogenic Effect of Hypericin, the Bioactive Component

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cytotoxic and Apoptogenic Effect of Hypericin, the Bioactive Component Mirmalek et al. Cancer Cell Int (2016) 16:3 DOI 10.1186/s12935-016-0279-4 Cancer Cell International PRIMARY RESEARCH Open Access Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF‑7 human breast cancer cell line Seyed Abbas Mirmalek1, Mohammad Amin Azizi2, Ehsan Jangholi3, Soheila Yadollah‑Damavandi3, Mohammad Amin Javidi4, Yekta Parsa3,7*, Tina Parsa3, Seyed Alireza Salimi‑Tabatabaee2, Hossein Ghasemzadeh kolagar5 and Reza Alizadeh‑Navaei6 Abstract Background: Breast cancer is the most prevalent malignancies among the women that have a high mortality. Previ‑ ous studies demonstrated that hypericin, a bioactive component of Hypericum perforatum have a cytotoxic effect on the malignant cell lines. However, an anti-carcinogenic activity of hypericin on MCF-7 is uncertain. To investi‑ gate the cytotoxic effect of hypericin on MCF-7 cells, a human breast adenocarcinoma cell-line, that resistance to chemotherapy. Methods: The MCF-7 and fibroblast (as normal cell line) were treated with various concentrations of hypericin, and Cisplatin as a positive control for 24 and 48 h. Cytotoxicity activity was measured and confirmed by MTT assay and Trypan blue staining, respectively. In addition, Apoptosis were determined by Annexin V/Propidium Iodide assay. Immunocytochemistry (ICC) analysis for bcl2 and p53 proteins performed to further investigate different expression of these genes in different samples. Results: Both cisplatin and the hypericin exhibited a dose-dependent cytotoxic effect in the MCF-7 cell line. Although the LD50 of the hypericin was significantly lower when compared to cispaltin (5 vs. 20 μg/ml), it continued to decrease the growth rate of the MCF-7 cells when tested at higher concentration than LD50. In contrast, cisplatine, at higher concentration than LD50, completely inhibited the growth of the MCF-7 in 48 h. Regarding Annexin V/ Propidium results, treatment of MCF-7 cells with LD50 concentration of cisplatin and hypericin showed 60 and 52 % apoptosis in 24 h, respectively. ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor forma‑ tion/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Conclusions: Considering that hypericin showed to be cytotoxic, it seems to be a chemopreventive agent and a good candidate for antineoplastic drug development. Keywords: MCF-7, Breast Cancer, Apoptosis, Hypericum perforatum, Hypericin, Cytotoxic *Correspondence: [email protected] 7 Medical Research Center, Azad University, Tehran Medical Branch, Attarimoqaddam Ave, Haqani Ave, Dr. Shariati St, Tehran, P. O. BOX : 19395‑1495, Iran Full list of author information is available at the end of the article © 2016 Mirmalek et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Mirmalek et al. Cancer Cell Int (2016) 16:3 Page 2 of 9 Background studies of H. perforatum revealed that the main chemical Breast cancer is one of the most common human malig- components are flavonoids, phloroglucinols and naph- nancies, accounting for 22 % of all cancers diagnosed in thodiathrones, of these, the content of flavonoids are the women and among the most frequent causes of cancer richest [13]. mortality in women worldwide [1, 2]. Metastatic breast Hypericin is one of the main constitute of H. perfora- cancer is considered incurable with median survival esti- tum, which in addition to its well-known anti-depres- mates of around 2–3 years, nevertheless treatments with sant activity has been proven to exhibit potent cytotoxic endocrine, cytotoxic, or targeted therapies can improve and pro-apoptotic effects against tumor cell lines in or preserve the quality of life and extend endurance. low micro molar concentrations, and to inhibit tumor- Breast cancer represents a complex and heterogeneous induced angiogenesis [8, 14]. disease comprising distinct pathologies with specific his- Although, extensive research has been carried out on tological features, therapeutic responses, metastatic dis- anti-carcinogenic activity of H. perforatum, no single semination patterns, and patient outcomes [3]. study exists which in MCF-7 cells [15–17]. Hence, this For the first time, Soule et al. [4] introduced the MCF-7 study was aimed to determine the antineoplastic activity cell line, which was derived from a patient with meta- of hypericin on human breast cell line MCF-7. static breast cancer. Despite many studies were estab- lished MCF-7 cells as the first hormone-responsive breast Results cancer cell line [5]. The benefit of the MCF-7 cell line as MTT assay an investigative tool led to its adoption in laboratories To determine cytotoxicity effect of hypericin on the worldwide [5, 6]. Various evidences include the ability MCF-7 cell viability MTT assay performed. As it is to undergo DNA fragmentation, differential sensitivi- shown in Fig. 1, the LD50 for 24 h for hypericin evalu- ties to estrogens and anti-estrogens, differential expres- ated to be 5 (μg/ml); and that of cisplatin was 20 (μg/ml). sion of estrogen receptors (ER), ER-mRNA, progesterone Treatment of fibroblasts (as a normal cell line) with the receptors and differences in tumorigenicity and prolifera- concentrations up to 30 (μg/ml) of hypericin and/or cis- tive rates. It has been demonstrated that the MCF-7 cell platin have not significant effect on the cells survival in line is a novel tool for the subject area of breast cancer 24 h (P = 0.062 and P = 0.054, respectively). resistance to chemotherapy, because it seems to mirror LD50 for 48 h for hypericin evaluated to be 0.5 (μg/ml) the heterogeneity of tumor cells in vivo [7]. The human (Fig. 2a); and that of cisplatin was 7.5 (μg/ml) (Fig. 2b). breast cancer cell line MCF-7 provides an unlimited Interestingly cells viability increased with the increase in source of homogenous self-replicating material, free of hypericin concentration. Treatment of fibroblasts with contaminating stromal cells, and can be easily cultured in the concentrations up to 10 (μg/ml) of hypericin and 15 simple standard media. Such a cell line is ideal to study (μg/ml) of cisplatin have not significant effect on the cells the interaction between a chemo-preventive drug and a survival in 48 h. cancer cell. The mechanism by which a chemo-preven- tive drug inhibits the proliferation of a cancer cell can be Flow cytometery better evaluated in vitro where the other physiological AnnexinV/PI flow cytometery was performed to quan- regulatory mechanisms, which are present in the in vivo tify cells that underwent apoptosis after cisplatin and system, are absent. hypericin treatment. As it is shown in Fig. 3, treatment Exploring the plant chemical diversity appears to be a of MCF-7 cells with LD50 concentration of cisplatin vital strategy for development of novel anticancer drugs and hypericin showed 60 and 52 % apoptosis in 24 h, characterized by alternative mode of action or lower respectively. toxicity. The intensive screening of plant-derived com- pounds for antineoplastic activity during the last several Trypan blue staining decades has contributed to the founding of various drug To further investigate the effect of hypericin on MCF-7 classes occupying a substantial portion of the anticancer cells death, trypan blue staining performed. After stain- drug market [8]. Recent evidence suggests that the mem- ing cells which had treated with 0.5 (μg/ml) concentra- bers of the Guttiferae family, e.g. diverse Hypericum, tion of hypericin or 7.5 (μg/ml) concentration of cisplatin Garcinia, Clusia, Cratoxylumspecies, appear to be a valu- for 48 h, cells became blue (Fig. 4a, b). Interestingly stain- able resource of cytotoxic compounds [8–10]. Hypericum ing cells which had treated with hypericin in higher con- perforatum, known as St. John’s wort, is the most stud- centration than LD50 [>0.5 (μg/ml)] did not became blue ied of Hypericum species and it is known for its phar- (Fig. 4c). However, cells which had treated with cisplatin macological antidepressant activities, its antiviral and in higher concentration of LD50 [>7.5 (μg/ml)], became antibacterial properties [11, 12]. Previous phytochemical blue after staining. Mirmalek et al. Cancer Cell Int (2016) 16:3 Page 3 of 9 Fig. 1 MTT assay results for cisplatin and hypericin in 24 h on MCF‑7 cell line. Treatment of MCF‑7 cells with 5 (μg/ml) concentration of hypericin showed 50 % cell death ( LD50 or IC50) (a, blue column), whereas LD50 of cisplatin in this time calculated to be 20 (μg/ml) (b, blue = column).*P < 0.05, **P < 0.01 Fig. 2 MTT assay results for cisplatin and hypericin in 48 h on MCF‑7 cell line. Treatment of MCF‑7 cells with 0.5 (μg/ml) concentration of hypericin showed 50 % cell death ( LD50 or IC50) (a, blue column), whereas LD50 of cisplatin in this time calculated to be 7.5 (μg/ml) (b, blue column). = *P < 0.05, **P < 0.01 Expression of bcl2 and p53 in different samples extracted from the H. perforatum or chemically synthe- To confirm that either treatment of cells with hypercin sized. It has been used for the photodynamic therapy of and/or cisplatin induce cell death via apoptosis and cancer and other conditions [19].
Load more

Recommended publications
  • Activity of Selected Group of Monoterpenes in Alzheimer's
    International Journal of Molecular Sciences Review Activity of Selected Group of Monoterpenes in Alzheimer’s Disease Symptoms in Experimental Model Studies—A Non-Systematic Review Karolina Wojtunik-Kulesza 1,*, Monika Rudkowska 2, Kamila Kasprzak-Drozd 1,* , Anna Oniszczuk 1 and Kinga Borowicz-Reutt 2 1 Department of Inorganic Chemistry, Medical University of Lublin, Chod´zki4a, 20-093 Lublin, Poland; [email protected] 2 Independent Experimental Neuropathophysiology Unit, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland; [email protected] (M.R.); [email protected] (K.B.-R.) * Correspondence: [email protected] (K.W.-K.); [email protected] (K.K.-D.) Abstract: Alzheimer’s disease (AD) is the leading cause of dementia and cognitive function im- pairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes—low-molecular compounds with anti-inflammatory, antioxidant, Citation: Wojtunik-Kulesza, K.; enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review Rudkowska, M.; Kasprzak-Drozd, K.; focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes Oniszczuk, A.; Borowicz-Reutt, K. and monoterpenoids for which possible mechanisms of action have been explained. The main body Activity of Selected Group of of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic Monoterpenes in Alzheimer’s and sleep-regulating effects as determined by in vitro and in silico tests—followed by validation in Disease Symptoms in Experimental in vivo models.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Download Supplementary
    Supplementary Materials: High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2 Olujide O. Olubiyi1,2*, Maryam Olagunju1, Monika Keutmann1, Jennifer Loschwitz1,3, and Birgit Strodel1,3* 1 Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, Jülich, Germany 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria 3 Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany * Corresponding authors: [email protected], [email protected] List of Figures S1 Chemical fragments majorly featured in the top performing 9,515 synthetic com- pounds obtained from screening against the crystal structure of the SARS-CoV-2 main protease 3CLpro. .................................. 2 S2 Chemical fragments majorly featured in the top 2,102 synthetic compounds obtained from ensemble docking and application of cutoff values of ∆G ≤ −7.0 kcal/mol and ddyad ≤ 3.5 Å. ............................ 2 S3 The poses and 3CLpro–compound interactions of phthalocyanine and hypericin. 3 S4 The poses and 3CLpro–compound interactions of the four best non-FDA-approved and investigational drugs. ............................... 4 S5 The poses and 3CLpro–compound interactions of zeylanone and glabrolide. 5 List of Tables S1 Names and properties of the compounds binding best to the active site of 3CLpro. 6 1 Supporting Material: High throughput virtual screening for 3CLpro inhibitors Figure S1: Chemical fragments majorly featured in the top performing 9,515 synthetic com- pounds obtained from screening against the crystal structure of the SARS-CoV-2 main pro- tease 3CLpro. The numbers represent the occurrence in absolute numbers.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]
  • Antiproliferative Effects of St. John's Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies
    International Journal of Molecular Sciences Review Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies Alessandro Allegra 1,* , Alessandro Tonacci 2 , Elvira Ventura Spagnolo 3, Caterina Musolino 1 and Sebastiano Gangemi 4 1 Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125 Messina, Italy; [email protected] 2 Clinical Physiology Institute, National Research Council of Italy (IFC-CNR), 56124 Pisa, Italy; [email protected] 3 Section of Legal Medicine, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Via del Vespro, 129, 90127 Palermo, Italy; [email protected] 4 School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-221-2364 Abstract: Hypericum is a widely present plant, and extracts of its leaves, flowers, and aerial elements have been employed for many years as therapeutic cures for depression, skin wounds, and respiratory and inflammatory disorders. Hypericum also displays an ample variety of other biological actions, such as hypotensive, analgesic, anti-infective, anti-oxidant, and spasmolytic abilities. However, recent investigations highlighted that this species could be advantageous for the cure of other pathological situations, such as trigeminal neuralgia, as well as in the treatment of cancer. This review focuses on the in vitro and in vivo antitumor effects of St. John’s Wort (Hypericum perforatum), its derivatives, and other Hypericum species in hematologic malignancies.
    [Show full text]
  • Crixivan® (Indinavir Sulfate) Capsules
    CRIXIVAN® (INDINAVIR SULFATE) CAPSULES DESCRIPTION CRIXIVAN* (indinavir sulfate) is an inhibitor of the human immunodeficiency virus (HIV) protease. CRIXIVAN Capsules are formulated as a sulfate salt and are available for oral administration in strengths of 100, 200, 333, and 400 mg of indinavir (corresponding to 125, 250, 416.3, and 500 mg indinavir sulfate, respectively). Each capsule also contains the inactive ingredients anhydrous lactose and magnesium stearate. The capsule shell has the following inactive ingredients and dyes: gelatin, titanium dioxide, silicon dioxide and sodium lauryl sulfate. The chemical name for indinavir sulfate is [1(1S,2R),5(S)]-2,3,5-trideoxy-N-(2,3-dihydro-2- hydroxy-1H-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1- piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate (1:1) salt. Indinavir sulfate has the following structural formula: Indinavir sulfate is a white to off-white, hygroscopic, crystalline powder with the molecular formula C36H47N5O4 • H2SO4 and a molecular weight of 711.88. It is very soluble in water and in methanol. MICROBIOLOGY Mechanism of Action: HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Antiretroviral Activity In Vitro: The in vitro activity of indinavir was assessed in cell lines of lymphoblastic and monocytic origin and in peripheral blood lymphocytes.
    [Show full text]
  • Assessment Report on Hypericum Perforatum L., Herba
    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Chinese Herbal Medicine for the Treatment of Depression: Effects on the Neuroendocrine-Immune Network
    pharmaceuticals Review Chinese Herbal Medicine for the Treatment of Depression: Effects on the Neuroendocrine-Immune Network Chan Li 1,2, Bishan Huang 1 and Yuan-Wei Zhang 1,3,* 1 School of Life Sciences, Guangzhou University, Guangzhou 510006, China; [email protected] (C.L.); [email protected] (B.H.) 2 Department of Psychiatry, School of Medicine Yale University, New Haven, CT 06511, USA 3 Department of Pharmacology, School of Medicine Yale University, New Haven, CT 06511, USA * Correspondence: [email protected] Abstract: The neuroimmune and neuroendocrine systems are two critical biological systems in the pathogenesis of depression. Clinical and preclinical studies have demonstrated that the activation of the neuroinflammatory response of the immune system and hyperactivity of the hypothalamus– pituitary–adrenal (HPA) axis of the neuroendocrine system commonly coexist in patients with depression and that these two systems bidirectionally regulate one another through neural, im- munological, and humoral intersystem interactions. The neuroendocrine-immune network poses difficulties associated with the development of antidepressant agents directed toward these biological systems for the effective treatment of depression. On the other hand, multidrug and multitarget Chinese Herbal Medicine (CHM) has great potential to assist in the development of novel medica- tions for the systematic pharmacotherapy of depression. In this narrative essay, we conclusively analyze the mechanisms of action of CHM antidepressant constituents and formulas, specifically through the modulation of the neuroendocrine-immune network, by reviewing recent preclinical studies conducted using depressive animal models. Some CHM herbal constituents and formulas are highlighted as examples, and their mechanisms of action at both the molecular and systems levels are discussed.
    [Show full text]